ES2096207T3 - Prevencion y tratamiento de aterosclerosis. - Google Patents

Prevencion y tratamiento de aterosclerosis.

Info

Publication number
ES2096207T3
ES2096207T3 ES93303526T ES93303526T ES2096207T3 ES 2096207 T3 ES2096207 T3 ES 2096207T3 ES 93303526 T ES93303526 T ES 93303526T ES 93303526 T ES93303526 T ES 93303526T ES 2096207 T3 ES2096207 T3 ES 2096207T3
Authority
ES
Spain
Prior art keywords
arteriosclerosis
present
patient
treatment
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93303526T
Other languages
English (en)
Inventor
Dennis I Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Application granted granted Critical
Publication of ES2096207T3 publication Critical patent/ES2096207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION PRESENTA UN METODO PARA EL TRATAMIENTO DE LA ARTERIOSCLEROSIS. EL METODO COMPRENDE EL PASO DE ADMINISTRAR A UN PACIENTE QUE TIENE ARTERIOSCLEROSIS, UNA COMPOSICION DE NO CISTEINA, DE NO TIOL QUE ESTIMULARA LA SINTESIS INTRACELULAR DE GLUTATION. EN UNA REALIZACION, LA COMPOSICION DE NO CISTEINA, NO TIOL ES L EN UNA REALIZACION DE LA PRESENTE INVENCION, LA PRESENTE INVENCION PROPORCIONA UN METODO PARA PREVENIR LAS LESIONES DE ARTERIOSCLEROSIS EN UN PACIENTE CON RIESGO DE LA MISMA. ADEMAS, LA PRESENTE INVENCION SE REFIERE A UN METODO PARA PREVENIR REESTENOSIS EN UN PACIENTE QUE PADECE UN PROCESO INVASIVO PARA TRATAR LA ARTERIOSCLEROSIS.
ES93303526T 1992-08-17 1993-05-06 Prevencion y tratamiento de aterosclerosis. Expired - Lifetime ES2096207T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/930,183 US5306724A (en) 1992-08-17 1992-08-17 Method for preventing and treating atherosclerosis

Publications (1)

Publication Number Publication Date
ES2096207T3 true ES2096207T3 (es) 1997-03-01

Family

ID=25459031

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93303526T Expired - Lifetime ES2096207T3 (es) 1992-08-17 1993-05-06 Prevencion y tratamiento de aterosclerosis.

Country Status (7)

Country Link
US (1) US5306724A (es)
EP (1) EP0583865B1 (es)
JP (1) JPH06172175A (es)
AU (1) AU663373B2 (es)
CA (1) CA2103644A1 (es)
DE (1) DE69306335T2 (es)
ES (1) ES2096207T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5783596A (en) * 1992-10-30 1998-07-21 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
AU7252896A (en) * 1995-10-02 1997-04-28 Trustees Of Columbia University In The City Of New York, The Biochemical markers of ischemia
CN1132577C (zh) * 1996-09-05 2003-12-31 研究发展基金会 用咖啡酸苯乙酯抑制核转录因子NF－kB
AU763042B2 (en) * 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53119866A (en) * 1977-03-25 1978-10-19 Yoshitomi Pharmaceut Ind Ltd 5-aryloxy-oxazoleakanoic acid derivatives and their preparation
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
DE3722647A1 (de) * 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid

Also Published As

Publication number Publication date
EP0583865A1 (en) 1994-02-23
EP0583865B1 (en) 1996-12-04
JPH06172175A (ja) 1994-06-21
DE69306335D1 (de) 1997-01-16
CA2103644A1 (en) 1994-02-18
US5306724A (en) 1994-04-26
DE69306335T2 (de) 1997-05-28
AU663373B2 (en) 1995-10-05
AU3838793A (en) 1994-02-24

Similar Documents

Publication Publication Date Title
PT100279A (pt) Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega
DE69706566T2 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
DE69530594D1 (de) Verfahren und mittel zur arzneistoffverabreichung
MD990262A (en) Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease
ES2096207T3 (es) Prevencion y tratamiento de aterosclerosis.
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
BR9509006A (pt) Composiçao para aplicaçao tópica na pele composiçao farmacêutica uso de um inibidor de síntese de colesterol e processo para o tratamento mitigaçao ou prevençao de distúrbios de pele
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
BR9907770A (pt) Mistura sinérgica de produtos naturais e seu uso
PT1102586E (pt) Utilizacao de extractos de ginkgo biloba para a preparacao de um medicamento para o tratamento da esclerose lateral amiotrofica
DE69635754D1 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
NO975177L (no) Farmasöytiske sammensetninger for behandling av alkoholavhengighet
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69525631D1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
BR0113101A (pt) Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional
ATE207756T1 (de) Pharmazeutische zusammensetzung, die muirapuama und pflanzenwürmer enthaelt
PT825859E (pt) Uso de forscoline ou extractos que o contenham na producao de um medicamento para o tratamento da dependencia do alcool
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
KR940003550A (ko) 노인성 치매 예방 및 치료방법
UA10254A (uk) Спосіб лікування цукрового діабету
UA12447A (uk) Спосіб профілактики професійhого броhхіту у робітників пилоhебезпечhих професій з докліhічhими формами хвороби і зhижеhим імуhітетом
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 583865

Country of ref document: ES